Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Trametinib in Treating Patients with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Multiple Cancer Types

This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Pediatric Leukemia, Pediatrics
II
Borinstein, Scott
NCT03190915
COGADVL1521

Expanded Access to Trametinib for a child with Plexiform Neurofibroma in NF1

Pediatrics

Pediatrics
N/A
Esbenshade, Adam
VICCPED2251

Dabrafenib Combined with Trametinib after Radiation Therapy in Treating Patients with Newly-Diagnosed High-Grade Glioma

Multiple Cancer Types

This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib after radiation therapy may work better than treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade glioma.
Neuro-Oncology, Pediatrics
II
Pastakia, Devang
NCT03919071
COGACNS1723

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Multiple Cancer Types

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Miscellaneous, Phase I
I
Iams, Wade
NCT04185883
VICCPHI2025

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: